,,trastuzumab deruxtecan
daiichi sankyo,astrazeneca,roche,astrazeneca,daiichi sankyo
['trastuzumab', 'destiny,breast,03', 'breast', 'trastuzumab deruxtecan', 'mbc', 'destiny-breast03', 'bcsm']
safety follow-up analysis of the phase 3 destiny-breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with her2-positive unresectable or metastatic breast cancer. #mbc #bcsm #asco22 
Oncology news and insights from leading researchers and cancer centers.